| abstract |
The present invention provides a novel means capable of suppressing the resistance of an anticancer drug to cancer cells. The present invention provides an anticancer drug resistance inhibitor containing, as an active ingredient, β1,3-N-acetylglucosaminyltransferase 6 or a specific derivative thereof, which controls biosynthesis of the core 3 structure of O-glycan. [Effect] According to the anticancer drug resistance inhibitor of the present invention, the drug excretion activity of P-glycoprotein, which is one of the drug excretion transporters, is suppressed. It is possible to suppress the resistance to an anticancer agent and maintain the effect of the anticancer agent. [Selection] Figure 4 |